Quantifying the economic impact of government and charity funding of medical research on private research and development funding in the United Kingdom

BMC Medicine

Volumn 14, Issue 1, 2016, Pages

  Sussex, Jon ^a,b   Feng, Yan ^b   Mestre Ferrandiz, Jorge ^b   Pistollato, Michele ^b   Hafner, Marco ^a   Burridge, Peter ^c   Grant, Jonathan ^d  

^a RAND CORPORATION   (United States)

^b Office of Health Economics   (United Kingdom)

^c UNIVERSITY OF YORK   (United Kingdom)

^d KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Biomedical and health research; Elasticities; Medical research charities; Pharmaceuticals; Rate of return; Research investment; Value of health; Vector error correction model

Indexed keywords

ARTICLE; CANCER RESEARCH; CARDIOVASCULAR DISEASE; DRUG INDUSTRY; DRUG MARKETING; ECONOMIC ASPECT; FUNDING; HUMAN; INVESTMENT; MANAGER; MEDICAL RESEARCH; SENSITIVITY ANALYSIS; STATISTICAL MODEL; UNITED KINGDOM; ECONOMICS; EPIDEMIOLOGY; FINANCIAL MANAGEMENT; GOVERNMENT; HEALTH CARE COST; NEOPLASM; PRIVATE SECTOR; PUBLIC SECTOR; RESEARCH; SOCIAL WELFARE; STATISTICS AND NUMERICAL DATA;

BIOMEDICAL RESEARCH; CHARITIES; FINANCIAL MANAGEMENT; GOVERNMENT; HEALTH EXPENDITURES; HUMANS; MODELS, ECONOMETRIC; NEOPLASMS; PRIVATE SECTOR; PUBLIC SECTOR; RESEARCH; UNITED KINGDOM;

EID: 84958967283     PISSN: None     EISSN: 17417015     Source Type: Journal    
DOI: 10.1186/s12916-016-0564-z     Document Type: Article

References (44)

1. Breschi S, Lissoni F. Knowledge spillovers and local innovation systems. Ind Corp Change. 2001;10(4):975-1005.
2. Cockburn I, Henderson R. Absorptive capacity, co-authoring behavior and the organization of research in drug discovery. J Ind Econ. 1998;66(2):157-82.
3. Cockburn IM, Henderson RM. Publicly funded science and the productivity of the pharmaceutical industry. In: Jaffe AB, Lerner J, Stern S, editors. Innovation Policy and the Economy, vol. 1. Boston, MA: MIT Press; 1980. p. 1-34.
4. HERG OHE, Europe RAND. Medical research: what's it worth? Estimating the economic benefits from medical research in the UK. Report for the Medical Research Council, the Wellcome Trust and the Academy of Medical Sciences. London: Wellcome Trust; 2008.
5. Toole A. Does public scientific research complement private investment in research and development in the pharmaceutical industry? J Law Econ. 2007;50:81-104.
6. Ward MR, Dranove D. The vertical chain of research and development in the pharmaceutical industry. Econ Inq. 1995;33:70-8.
7. Chakravarthy R, Cotter K, DiMasi J, Milne C-P, Wendel N. Public and Private Sector Contributions to the Research & Development of the Most Transformational Drugs of the Last 25 Years. A Tufts Center for the Study of Drug Development White Paper. Boston, MA: Tufts University School of Medicine, 2015.
8. Glover M, Buxton M, Guthrie S, Hanney S, Pollitt A, Grant J. Estimating the returns to UK publicly funded cancer-related research in terms of the net value of improved health outcomes. BMC Med. 2014;12:99.
9. Cancer Research UK. Medical Research and the Spending Review. 2010. http://www.cancerresearchuk.org/prod_consump/groups/cr_common/nre/pol/documents/generalcontent/cr_048533.pdf. Accessed 3 February 2016.
10. Association of Medical Research Charities. Written Submission to the Comprehensive Spending Review. 2010. http://www.amrc.org.uk/publications/submission-department-business-innovation-and-skills-part-comprehensive-spending-review. Accessed 3 February 2016.
11. Academy of Medical Sciences. Initial Response to the Spending Review Consultation. 2010. http://www.acmedsci.ac.uk/publications/. Accessed 3 August 2015
12. Councils EMR. White Paper II: A Stronger Biomedical Research for a Better European Future. Strasbourg: European Science Foundation; 2011.
13. ONS. Gross domestic product: preliminary estimate, Q1 2015. London: Office for National Statistics. http://www.ons.gov.uk/ons/rel/gva/gross-domestic-product--preliminary-estimate/q1-2015/index.html. Accessed 3 February 2016.
14. NCVO. NCVO UK civil society almanac 2014. London: National Council for Voluntary Organisations; 2014. http://data.ncvo.org.uk/a/almanac14/what-is-the-sectors-contribution-to-the-economy/. Accessed 3 February 2016.
15. Jaffe AB. Technological opportunity and spillovers of R&D: evidence from firms' patents, profits, and market value. Am Econ Rev. 1986;76(5):984-1001.
16. Frontier Economics. Rates of return to investment in science and innovation. A report prepared for the Department of Business Innovation and Skills. London: London Frontier Economics; 2014. http://www.frontier-economics.com/publications/rates-of-return-to-investment-in-science-and-innovation/. Accessed 3 February 2016.
17. Haskel J, Hughes A, Bascavusoglu-Moreau E. The Economic Significance of the UK Science Base. London: Campaign for Science and Engineering, 2014. http://www.sciencecampaign.org.uk/UKScienceBase.pdf. Accessed 3 August 2015.
18. Engle RF, Granger CWJ. Co-integration and error correction: representation, estimation, and testing. Econometrica. 1987;55:251-76.
19. Granger CWJ. Empirical Modelling in Economics. Cambridge: Cambridge University Press; 1999.
20. Health Research Classification System, UK Clinical Research Collaboration. http://www.hrcsonline.net/hc/view. Accessed 3 August 2015.
21. Journal Classification System, Thomson Reuters. http://ip-science.thomsonreuters.com/mjl/scope/scope_scie/. Accessed 3 August 2015.
22. GDP deflators at market prices, and money GDP: December 2013, National Statistics. https://www.gov.uk/government/statistics/gdp-deflators-at-market-prices-and-money-gdp-march-2013. Accessed 3 February 2016.
23. Science, engineering and technology statistics 2013. Department for Business, Innovation and Skill. http://www.ons.gov.uk/ons/rel/rdit1/science--engineering-and-technology-statistics/2013/index.html. Accessed 3 February 2016.
24. Cabinet Office. Annual Review of Government Funded R&D. London: Her Majesty's Stationery Office; 1984.
25. Acemoglu D, Linn J. Market size in innovation: theory and evidence from the pharmaceutical industry. Q J Econ. 2004;119(3):1049-90.
26. Cerda RA. Endogenous innovations in the pharmaceutical industry. J Evol Econ. 2007;17(4):473-515.
27. Rake B. Determinants of pharmaceutical innovation: the role of technological opportunities revisited. Jena Economic Research Papers. Jena, Germany: Friedrich-Schiller-University; 2012.
28. Dubois P, de Mouzon O, Scott-Morton F, Seabright P. Market size and pharmaceutical innovation. Institut d'Economie Industrielle Working Paper. Institut d'Economie Industrielle. Toulouse: University of Toulouse; 2011.
29. IMS Health. World review. Annual publication 1983-2013. Danbury CT, USA: IMS Health Incorporated.
30. Eviews 8 User's Guide II. Irvine CA, USA. http://www.eviews.com. Accessed 3 February 2016.
31. Enders W. Applied Econometric Time Series. Hoboken: Wiley; 1995. Especially chapter 6. Cointegration and Error Correction Models.
32. Garratt A, Lee K, Pesaran MH, Shin Y. Global and National Macroeconometric Modelling. Oxford: Oxford University Press; 2012.
33. Dickey DA, Fuller WA. Distribution of the estimators for autoregressive time series with a unit root. J Am Stat Assoc. 1979;74:427-31.
34. Nielsen B. Order determination in general vector autoregressions. Working paper. Oxford: Department of Economics, University of Oxford and Nuffield College, 2001. http://ideas.repec.org/p/nuf/econwp/0110.html. Accessed 3 February 2016.
35. Paulsen J. Order determination of multivariate autoregressive time series with unit roots. J Time Ser Anal. 1984;5:115-27.
36. Tsay RS. Order selection in nonstationary autoregressive models. Ann Stat. 1984;12:1425-33.
37. Johansen S. Likelihood-Based Inference in Cointegrated Vector Autoregressive Models. Oxford: Oxford University Press; 1995.
38. Pantula SG. Testing for unit roots in time series data. Economet Theor. 1989;5:256-71.
39. Boyack KW, Jordan P. Metrics associated with NIH funding: a high-level view. J Am Med Inform Assoc. 2011;18:423-31.
40. Mossinghoff, G. Overview of the Hatch-Waxman Act and its impact on the drug development process. Food and Drug Law Journal. 1999;54:187-194.
41. Pesaran MH, Shin Y. Generalised impulse response analysis in linear multivariate models. Econ Lett. 1998;58:17-29.
42. Koop G, Pesaran MH, Potter SM. Impulse response analysis in nonlinear multivariate models. J Econometrics. 1996;74:119-47.
43. RAND Europe and Office of Health Economics. Enhancing the benefits from biomedical and health research spillovers between public, private and charitable sectors in the UK. Santa Monica, CA: RAND Corporation; 2010. http://www.rand.org/pubs/occasional_papers/OP319. Accessed 3 August.
44. HM Treasury. The Green Book: Appraisal and Evaluation in Central Government. London: HM Treasury, 2011. https://www.gov.uk/government/publications/the-green-book-appraisal-and-evaluation-in-central-governent. Accessed 3 February 2016.